Sunday, July 11, 2021 12:41:11 PM
Proof: No Bod. Fake scientfic board of people who did minimal consulting. Lawsuit for $1.2 million in unpaid bills to Chemdiv who will WIN and get the rights to all the work they did. No employees, just Koos. Bogus deal with another Regen wanna be with a failed business plan copied from Koos.
All past employees want nothing to do with Koos (hence why he's the only guy at Regen).
IP that is worth 2 cents per share and that's still too expensive as the IP isn't even tested (hence why no BP has any interest and why LILLY didn't use the info Regen gained to further the partnership after Lilly allowed Regen to use their molecules).
And if Koos was legit, he would have done the hard work to have put his companies on NASDAQ and not the OTC. Only shady business people and scam companies use the OTC. Why do you think the SEC is cracking down on OTC companies?
UNDENIABLE!
Give it time.....RGBP will crash and crash hard and I'll still be here to remind you about how right I have been.
All past employees want nothing to do with Koos (hence why he's the only guy at Regen).
IP that is worth 2 cents per share and that's still too expensive as the IP isn't even tested (hence why no BP has any interest and why LILLY didn't use the info Regen gained to further the partnership after Lilly allowed Regen to use their molecules).
And if Koos was legit, he would have done the hard work to have put his companies on NASDAQ and not the OTC. Only shady business people and scam companies use the OTC. Why do you think the SEC is cracking down on OTC companies?
UNDENIABLE!
Give it time.....RGBP will crash and crash hard and I'll still be here to remind you about how right I have been.
FACTS are stubborn things
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
